These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35561817)

  • 1. Detection and assessment of alpha-synuclein in Parkinson disease.
    Tsao HH; Huang CG; Wu YR
    Neurochem Int; 2022 Sep; 158():105358. PubMed ID: 35561817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
    Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH
    J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.
    Kruse N; Mollenhauer B
    Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
    PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
    Hong Z; Shi M; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Leverenz JB; Baird G; Montine TJ; Hancock AM; Hwang H; Pan C; Bradner J; Kang UJ; Jensen PH; Zhang J
    Brain; 2010 Mar; 133(Pt 3):713-26. PubMed ID: 20157014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
    Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
    ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
    Lin WC; Lu CH; Chiu PY; Yang SY
    Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
    Førland MG; Öhrfelt A; Oftedal LS; Tysnes OB; Larsen JP; Blennow K; Zetterberg H; Alves G; Lange J
    Clin Chem Lab Med; 2017 Feb; 55(2):254-260. PubMed ID: 27474841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    Mollenhauer B; Bowman FD; Drake D; Duong J; Blennow K; El-Agnaf O; Shaw LM; Masucci J; Taylor P; Umek RM; Dunty JM; Smith CL; Stoops E; Vanderstichele H; Schmid AW; Moniatte M; Zhang J; Kruse N; Lashuel HA; Teunissen C; Schubert T; Dave KD; Hutten SJ; Zetterberg H
    J Neurochem; 2019 Apr; 149(1):126-138. PubMed ID: 30125936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
    J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tear α-synuclein as a biomarker for Parkinson's disease: A systematic review and meta-analysis.
    Akowuah PK; Owusu E; Totoe D
    Optom Vis Sci; 2024 Jul; 101(7):485-492. PubMed ID: 39094023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.